Using a positive selection, pooled screening approach, we infected the BRAF-mutant melanoma cell line UACC-62 with the pooled library and treated populations of the cells with either vehicle control or the MEK1/2 inhibitor AZD6244 at multiple doses yielding between 20% to 80% growth inhibition (150 nM, 750 nM, and 1.5 μM). This evidence concerns the gene BRAF and melanoma.